• 1

    Mahmoud AA, 1996. Strongyloidiasis. Clin Infect Dis 23 :949–952.

  • 2

    Keiser PB, Nutman TB, 2004. Stongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 17 :208–217.

  • 3

    Link K, Orenstein R, 1999. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South Med J 92 :728–731.

  • 4

    Cruz T, Reboucas G, Rocha H, 1966. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med 275 :1093–1096.

  • 5

    Civantos F, Robinson MJ, 1969. Fatal strongyloidiasis following corticosteroid therapy. Am J Dig Dis 14 :643–645.

  • 6

    Celedon JC, Mathur-Wagh U, Fox J, Garcia R, Wiest PM, 1994. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 73 :256–263.

    • Search Google Scholar
    • Export Citation
  • 7

    Gann PH, Neva FA, Gam AA, 1994. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 169 :1076–1079.

    • Search Google Scholar
    • Export Citation
  • 8

    Marti H, Haji HJ, Savioloi L, Chwaya HM, Mgeni AF, Ameir JS, Hatz C, 1996. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 55 :477–481.

    • Search Google Scholar
    • Export Citation
  • 9

    Nandy A, Addy M, Patra P, Bandyopashayay AK, 1995. Fulminating strongyloidiasis complicating Indian kalaazar. Trop Geogr Med 47 :139–141.

    • Search Google Scholar
    • Export Citation
  • 10

    Boken DJ, Leoni PA, Preheim LC, 1993. Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum. Clin Infect Dis 16 :123–126.

    • Search Google Scholar
    • Export Citation
  • 11

    Tarr PE, Miele PS, Peregoy KS, Smith MA, Neva FA, Lucey DR, 2003. Rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 68 :453–455.

    • Search Google Scholar
    • Export Citation
  • 12

    Chiodini PL, Reid AJC, Wiselka MJ, Firmin R, Foweraker J, 2000. Parenteral ivermectin in Strongyloides hyperinfection. Lancet 355 :43–44.

    • Search Google Scholar
    • Export Citation
  • 13

    Courouble G, Rouet F, Hermann-Storck C, Nicolas M, Candolfi E, Strobel M, Carme B, 2000. Human T-cell lymphotropic virus type I association with Strongyloides stercoralis: a case control study among Caribbean blood donors from Guadeloupe (French West Indies). J Clin Microbiol 38 :3903–3904.

    • Search Google Scholar
    • Export Citation
  • 14

    Yamaguchi K, Matutes E, Catovsky D, Galton DA, Nakada K, Takatsuki K, 1987. Strongyloides stercoralis as candidate cofactor for HTLV-I-induced leukaemogenesis. Lancet 2 :94–95.

    • Search Google Scholar
    • Export Citation
  • 15

    Porto AF, Neva FA, Bittencourt H, Lisboa W, Thompson R, Alcantara L, Carvalho EM, 2001. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol 23 :503–507.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

SUBCUTANEOUS IVERMECTIN AS A SAFE SALVAGE THERAPY IN STRONGYLOIDES STERCORALIS HYPERINFECTION SYNDROME: A CASE REPORT

View More View Less
  • 1 Départements de Microbiologie, Soins Intensifs de Pneumologie, et d’Oncologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Pairs, France; Université Paris V, Paris, France; Département de Parasitologie-Mycologie, Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France

Strongyloides stercoralis hyperinfection syndrome due to the acceleration of the autoinfective cycle of the nematode is a life-threatening form of the infection occurring in immunocompromised hosts. Intestinal ileus, which is commonly encountered in this form, may reduce the bioavailability and thus the efficacy of oral anthelminthic drugs used in the treatment of the S. stercoralis hyperinfection syndrome. We report the efficacy and safety of subcutaneous administration of ivermectin in a patient infected with human T cell lymphotropic virus type I with S. stercoralis hyperinfection syndrome who was unresponsive to an oral combination of ivermectin and albendazole.

Save